PROFILES - Connect with RTRN Researchers

David Calhoun
Title Investigator / Area Leader
Faculty Rank
Degree Ph.D.
Institution City College, CUNY
Department
Clusters
Address
City College, CUNY, Marshak Science Building
Covenant Avenue at 138th Street
City New York
State NY
Postal Code 10031
Telephone _
Fax
Email
QR Barcode

Narrative icon

 
Not Available

Publications icon

  Check NIH Public Access Policy Compliance

Loading
Please wait
1. Parikh V, Thaler E, Kato M, Gillespie MB, Nguyen S, Withrow K, Calhoun D, Soose R, Stevens D, Stevens S, Larsen C, Reddy M, Lakkireddy D. Early feasibility of Hypoglossal Nerve Upper Airway Stimulator in Patients with Cardiac Implantable Electronic Devices and Continuous Positive Airway Pressure-Intolerant Severe Obstructive Sleep Apnea. Heart Rhythm. 2018 Apr 17.
2. Calhoun DA. Fluid retention, aldosterone excess, and treatment of resistant hypertension. Lancet Diabetes Endocrinol. 2018 Apr 11.
3. Valaiyapathi B, Calhoun DA. Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome. Curr Hypertens Rep. 2018 Mar 19; 20(3):23.
4. Calhoun DA. Medical Versus Surgical Treatment of Primary Aldosteronism. Hypertension. 2018 Apr; 71(4):566-568.
5. Irvin MR, Booth JN, Sims M, Bress AP, Abdalla M, Shimbo D, Calhoun DA, Muntner P. The association of nocturnal hypertension and nondipping blood pressure with treatment-resistant hypertension: The Jackson Heart Study. J Clin Hypertens (Greenwich). 2018 Mar; 20(3):438-446.
6. Cai A, Calhoun DA. Antihypertensive Medications and Falls in the Elderly. Am J Hypertens. 2018 Feb 09; 31(3):281-283.
7. Flack JM, Calhoun D, Schiffrin EL. The New ACC/AHA Hypertension Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Am J Hypertens. 2018 Jan 12; 31(2):133-135.
8. Armario P, Calhoun DA, Oliveras A, Blanch P, Vinyoles E, Banegas JR, Gorostidi M, Segura J, Ruilope LM, Dudenbostel T, de la Sierra A. Prevalence and Clinical Characteristics of Refractory Hypertension. J Am Heart Assoc. 2017 Dec 07; 6(12).
9. Calhoun DA, Grassi G. True versus pseudoresistant hypertension. J Hypertens. 2017 Dec; 35(12):2367-2368.
10. Eirin A, Saad A, Woollard JR, Juncos LA, Calhoun DA, Tang H, Lerman A, Textor SC, Lerman LO. Glomerular Hyperfiltration in Obese African American Hypertensive Patients Is Associated With Elevated Urinary Mitochondrial-DNA Copy Number. Am J Hypertens. 2017 Nov 01; 30(11):1112-1119.
11. Dudenbostel T, Siddiqui M, Gharpure N, Calhoun DA. Refractory versus resistant hypertension: Novel distinctive phenotypes. J Nat Sci. 2017 Sep; 3(9).
12. Siddiqui M, Judd EK, Oparil S, Calhoun DA. White-Coat Effect Is Uncommon in Patients With Refractory Hypertension. Hypertension. 2017 09; 70(3):645-651.
13. Calhoun DA. Sleep disorders and hypertension risk. J Hum Hypertens. 2017 Jun; 31(6):371-372.
14. Cai A, Calhoun DA. Resistant Hypertension: An Update of Experimental and Clinical Findings. Hypertension. 2017 07; 70(1):5-9.
15. Ghazi L, Dudenbostel T, Hachem ME, Siddiqui M, Lin CP, Oparil S, Calhoun DA. 11-Beta Dehydrogenase Type 2 Activity Is Not Reduced in Treatment Resistant Hypertension. Am J Hypertens. 2017 May 01; 30(5):518-523.
16. Wolley MJ, Pimenta E, Calhoun D, Gordon RD, Cowley D, Stowasser M. Treatment of primary aldosteronism is associated with a reduction in the severity of obstructive sleep apnoea. J Hum Hypertens. 2017 Sep; 31(9):561-567.
17. Ghazi L, Oparil S, Calhoun DA, Lin CP, Dudenbostel T. Distinctive Risk Factors and Phenotype of Younger Patients With Resistant Hypertension: Age Is Relevant. Hypertension. 2017 05; 69(5):827-835.
18. Thomas SJ, Booth JN, Bromfield SG, Seals SR, Spruill TM, Ogedegbe G, Kidambi S, Shimbo D, Calhoun D, Muntner P. Clinic and ambulatory blood pressure in a population-based sample of African Americans: the Jackson Heart Study. J Am Soc Hypertens. 2017 Apr; 11(4):204-212.e5.
19. Vemulapalli S, Deng L, Patel MR, Kilgore ML, Jones WS, Curtis LH, Irvin MR, Svetkey LP, Shimbo D, Calhoun DA, Muntner P. National patterns in intensity and frequency of outpatient care for apparent treatment-resistant hypertension. Am Heart J. 2017 Apr; 186:29-39.
20. Siddiqui M, Calhoun DA. Refractory versus resistant hypertension. Curr Opin Nephrol Hypertens. 2017 01; 26(1):14-19.
21. Schiffrin EL, Calhoun DA, Flack JM, Ito S, Webb RC. Update From the Editors to Our Readers. Am J Hypertens. 2017 Jan; 30(1):1-2.
22. Thomas SJ, Calhoun D. Sleep, insomnia, and hypertension: current findings and future directions. J Am Soc Hypertens. 2017 Feb; 11(2):122-129.
23. Ghazi L, Dudenbostel T, Xing D, Ejem D, Turner-Henson A, Joiner CI, Affuso O, Azuero A, Oparil S, Calhoun DA, Rice M, Hage FG. Assessment of vascular function in low socioeconomic status preschool children: a pilot study. J Am Soc Hypertens. 2017 Feb; 11(2):101-109.
24. Dudenbostel T, Calhoun DA. Effects of Spironolactone and Renal Denervation Treatment on Blood Pressure and Its Variability-Different Aspects of Hypertension Treatment. Am J Hypertens. 2017 Jan; 30(1):12-15.
25. Bangalore S, Davis BR, Cushman WC, Pressel SL, Muntner PM, Calhoun DA, Kostis JB, Whelton PK, Probstfield JL, Rahman M, Black HR. Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT. Am J Med. 2017 Apr; 130(4):439-448.e9.
26. Biaggioni I, Calhoun DA. Sympathetic Activity, Hypertension, and The Importance of a Good Night's Sleep. Hypertension. 2016 12; 68(6):1338-1339.
27. Bhatt H, Ghazi L, Calhoun D, Oparil S. BP Targets in Hypertension: What Should We Do Now That SPRINT Is Out? Curr Cardiol Rep. 2016 Oct; 18(10):98.
28. Calhoun DA. Refractory and Resistant Hypertension: Antihypertensive Treatment Failure versus Treatment Resistance. Korean Circ J. 2016 Sep; 46(5):593-600.
29. Dudenbostel T, Calhoun DA. Use of Aldosterone Antagonists for Treatment of Uncontrolled Resistant Hypertension. Am J Hypertens. 2017 Feb; 30(2):103-109.
30. Calhoun DA. Spironolactone versus renal nerve denervation for treatment of uncontrolled resistant hypertension. J Hypertens. 2016 09; 34(9):1701-3.
31. Calhoun DA. Renal Nerve Denervation, Adherence, and Management of Resistant Hypertension. Circulation. 2016 Sep 20; 134(12):858-60.
32. Saddekni MB, Saag KG, Dudenbostel T, Oparil S, Calhoun DA, Sattui SE, Feig DI, Muntner P, Redden DT, Foster PJ, Rahn EJ, Biggers SR, Li P, Gaffo AL. The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale. Contemp Clin Trials. 2016 09; 50:238-44.
33. Dudenbostel T, Ghazi L, Liu M, Li P, Oparil S, Calhoun DA. Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension. Hypertension. 2016 10; 68(4):995-1003.
34. Bhandari SK, Shi J, Molnar MZ, Rasgon SA, Derose SF, Kovesdy CP, Calhoun DA, Kalantar-Zadeh K, Jacobsen SJ, Sim JJ. Comparisons of sleep apnoea rate and outcomes among patients with resistant and non-resistant hypertension. Respirology. 2016 11; 21(8):1486-1492.
35. Schiffrin EL, Calhoun DA, Flack JM. Do We Need a New Definition of Hypertension After SPRINT? Am J Hypertens. 2016 10; 29(10):1127-9.
36. Ghazi L, Dudenbostel T, Lin CP, Oparil S, Calhoun DA. Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status. J Hypertens. 2016 May; 34(5):1005-10.
37. Dudenbostel T, Siddiqui M, Oparil S, Calhoun DA. Refractory Hypertension: A Novel Phenotype of Antihypertensive Treatment Failure. Hypertension. 2016 06; 67(6):1085-92.
38. Corrêa NB, de Faria AP, Ritter AM, Sabbatini AR, Almeida A, Brunelli V, Calhoun DA, Moreno H, Modolo R. A practical approach for measurement of antihypertensive medication adherence in patients with resistant hypertension. J Am Soc Hypertens. 2016 Jun; 10(6):510-516.e1.
39. Pimenta E, Calhoun DA. Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension? Curr Hypertens Rep. 2016 Apr; 18(4):25.
40. Bhatt H, Siddiqui M, Judd E, Oparil S, Calhoun D. Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement. J Am Soc Hypertens. 2016 Jun; 10(6):493-9.
41. Muntner P, Becker RC, Calhoun D, Chen D, Cowley AW, Flynn JT, Grobe JL, Kidambi S, Kotchen TA, Lackland DT, Leslie KK, Li Y, Liang M, Lloyd A, Mattson DL, Mendizabal B, Mitsnefes M, Nair A, Pierce GL, Pollock JS, Safford MM, Santillan MK, Sigmund CD, Thomas SJ, Urbina EM. Introduction to the American Heart Association's Hypertension Strategically Focused Research Network. Hypertension. 2016 Apr; 67(4):674-80.
42. Krzywanski DM, Moellering DR, Westbrook DG, Dunham-Snary KJ, Brown J, Bray AW, Feeley KP, Sammy MJ, Smith MR, Schurr TG, Vita JA, Ambalavanan N, Calhoun D, Dell'Italia L, Ballinger SW. Endothelial Cell Bioenergetics and Mitochondrial DNA Damage Differ in Humans Having African or West Eurasian Maternal Ancestry. Circ Cardiovasc Genet. 2016 Feb; 9(1):26-36.
43. Schiffrin EL, Calhoun DA, Flack JM, Ito S, Webb RC. A Message From the New Editorial Team at the American Journal of Hypertension. Am J Hypertens. 2016 Jan; 29(1):1.
44. Judd E, Calhoun DA. Obesity, African American Race, Chronic Kidney Disease, and Resistant Hypertension: The Step Beyond Observed Risk. Hypertension. 2016 Feb; 67(2):275-7.
45. Schiffrin EL, Calhoun DA, Flack JM. SPRINT Proves that Lower Is Better for Nondiabetic High-Risk Patients, but at a Price. Am J Hypertens. 2016 Jan; 29(1):2-4.
46. Ellis AC, Patterson M, Dudenbostel T, Calhoun D, Gower B. Effects of 6-month supplementation with ß-hydroxy-ß-methylbutyrate, glutamine and arginine on vascular endothelial function of older adults. Eur J Clin Nutr. 2016 Feb; 70(2):269-73.
47. Siddiqui M, Dudenbostel T, Calhoun DA. Resistant and Refractory Hypertension: Antihypertensive Treatment Resistance vs Treatment Failure. Can J Cardiol. 2016 05; 32(5):603-6.
48. Calhoun DA. Editorial comment: change in leadership. J Hum Hypertens. 2015 Jun; 29(6):339.
49. Dudenbostel T, Acelajado MC, Pisoni R, Li P, Oparil S, Calhoun DA. Refractory Hypertension: Evidence of Heightened Sympathetic Activity as a Cause of Antihypertensive Treatment Failure. Hypertension. 2015 Jul; 66(1):126-33.
50. Sim JJ, Bhandari SK, Shi J, Reynolds K, Calhoun DA, Kalantar-Zadeh K, Jacobsen SJ. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int. 2015 Sep; 88(3):622-32.
51. Breaux-Shropshire TL, Whitt L, Oster RA, Lewis D, Shropshire TS, Calhoun DA. Results of an Academic, Health Care Worksite Weight Loss Contest for Southeastern Americans: Scale Back Alabama 2011-2013. Workplace Health Saf. 2015 Apr; 63(4):165-9.
52. Yano Y, Ning H, Muntner P, Reis JP, Calhoun DA, Viera AJ, Levine DA, Jacobs DR, Shimbo D, Liu K, Greenland P, Lloyd-Jones D. Nocturnal Blood Pressure in Young Adults and Cognitive Function in Midlife: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J Hypertens. 2015 Oct; 28(10):1240-7.
53. Gonzaga C, Bertolami A, Bertolami M, Amodeo C, Calhoun D. Obstructive sleep apnea, hypertension and cardiovascular diseases. J Hum Hypertens. 2015 Dec; 29(12):705-12.
54. Howard VJ, Tanner RM, Anderson A, Irvin MR, Calhoun DA, Lackland DT, Oparil S, Muntner P. Apparent Treatment-resistant Hypertension Among Individuals with History of Stroke or Transient Ischemic Attack. Am J Med. 2015 Jul; 128(7):707-14.e2.
55. Judd E, Calhoun DA. Management of hypertension in CKD: beyond the guidelines. Adv Chronic Kidney Dis. 2015 Mar; 22(2):116-22.
56. Biederman RW, Young AA, Doyle M, Devereux RB, Kortright E, Perry G, Bella JN, Oparil S, Calhoun D, Pohost GM, Dell'Italia LJ. Regional Heterogeneity in 3D Myocardial Shortening in Hypertensive Left Ventricular Hypertrophy: A Cardiovascular CMR Tagging Substudy to the Life Study. J Biomed Sci Eng. 2015 Mar 01; 8(3):213-225.
57. Meghdari M, Gao N, Abdullahi A, Stokes E, Calhoun DH. Carboxyl-terminal truncations alter the activity of the human a-galactosidase A. PLoS One. 2015; 10(2):e0118341.
58. Nikolova D, Rumley S, Calhoun D, Li Q, Hendry R, Samadi P, Bergman K. Scaling silicon photonic switch fabrics for data center interconnection networks. Opt Express. 2015 Jan 26; 23(2):1159-75.
59. Ashraf AP, Alvarez JA, Dudenbostel T, Calhoun D, Griffin R, Wang X, Hanks LJ, Gower BA. Associations between vascular health indices and serum total, free and bioavailable 25-hydroxyvitamin D in adolescents. PLoS One. 2014; 9(12):e114689.
60. Muntner P, Lewis CE, Diaz KM, Carson AP, Kim Y, Calhoun D, Yano Y, Viera AJ, Shimbo D. Racial differences in abnormal ambulatory blood pressure monitoring measures: Results from the Coronary Artery Risk Development in Young Adults (CARDIA) study. Am J Hypertens. 2015 May; 28(5):640-8.
61. Schiros CG, Desai RV, Venkatesh BA, Gaddam KK, Agarwal S, Lloyd SG, Calhoun DA, Denney TS, Dell'italia LJ, Gupta H. Left ventricular torsion shear angle volume analysis in patients with hypertension: a global approach for LV diastolic function. J Cardiovasc Magn Reson. 2014 Sep 26; 16:70.
62. Gupta A, Schiros CG, Gaddam KK, Aban I, Denney TS, Lloyd SG, Oparil S, Dell'Italia LJ, Calhoun DA, Gupta H. Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy. J Hum Hypertens. 2015 Apr; 29(4):241-6.
63. Yamal JM, Oparil S, Davis BR, Alderman MH, Calhoun DA, Cushman WC, Fendley HF, Franklin SS, Habib GB, Pressel SL, Probstfield JL, Sastrasinh S. Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT. J Am Soc Hypertens. 2014 Nov; 8(11):808-19.
64. Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun DA, Pressel SL, Black HR, Kostis JB, Probstfield JL, Whelton PK, Rahman M. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2014 Nov; 64(5):1012-21.
65. Modolo R, de Faria AP, Paganelli MO, Sabbatini AR, Barbaro NR, Nascimento BB, Ramos CD, Fontana V, Calhoun DA, Moreno H. Predictors of silent myocardial ischemia in resistant hypertensive patients. Am J Hypertens. 2015 Feb; 28(2):200-7.
66. White WB, Turner JR, Sica DA, Bisognano JD, Calhoun DA, Townsend RR, Aronow HD, Bhatt DL, Bakris GL. Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013. J Am Soc Hypertens. 2014 Oct; 8(10):743-57.
67. Breaux-Shropshire TL, Whitt L, Griffin RL, Shropshire AT, Calhoun DA. Characterizing workers participating in a worksite wellness health screening program using blood pressure control, self-monitoring, medication adherence, depression, and exercise. Workplace Health Saf. 2014 Jul; 62(7):292-300.
68. Ferdinand KC, White WB, Calhoun DA, Lonn EM, Sager PT, Brunelle R, Jiang HH, Threlkeld RJ, Robertson KE, Geiger MJ. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014 Oct; 64(4):731-7.
69. Diaz KM, Booth JN, Calhoun DA, Irvin MR, Howard G, Safford MM, Muntner P, Shimbo D. Healthy lifestyle factors and risk of cardiovascular events and mortality in treatment-resistant hypertension: the Reasons for Geographic and Racial Differences in Stroke study. Hypertension. 2014 Sep; 64(3):465-71.
70. Calhoun DA, Booth JN, Oparil S, Irvin MR, Shimbo D, Lackland DT, Howard G, Safford MM, Muntner P. Response to should more significance be granted to medication response to antihypertensives in patients with resistant hypertension? Hypertension. 2014 Apr; 63(4):e84.
71. Irvin MR, Booth JN, Shimbo D, Lackland DT, Oparil S, Howard G, Safford MM, Muntner P, Calhoun DA. Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. J Am Soc Hypertens. 2014 Jun; 8(6):405-13.
72. Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, Calhoun DA. Response to Comment on optimal treatment for resistant hypertension: the missing data on pulse wave velocity. Hypertension. 2014 Mar; 63(3):e17-8.
73. Judd E, Calhoun DA. Management of Resistant Hypertension: Do Not Give Up on Medication. Nephrol Self Assess Program. 2014 Mar; 13(2):57-63.
74. Judd E, Calhoun DA. Apparent and true resistant hypertension: definition, prevalence and outcomes. J Hum Hypertens. 2014 Aug; 28(8):463-8.
75. de la Sierra A, Calhoun DA, Vinyoles E, Banegas JR, de la Cruz JJ, Gorostidi M, Segura J, Ruilope LM. Heart rate and heart rate variability in resistant versus controlled hypertension and in true versus white-coat resistance. J Hum Hypertens. 2014 Jul; 28(7):416-20.
76. Judd EK, Calhoun DA, Warnock DG. Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels. Semin Nephrol. 2014; 34(5):532-9.
77. Tanner RM, Calhoun DA, Bell EK, Bowling CB, Gutiérrez OM, Irvin MR, Lackland DT, Oparil S, McClellan W, Warnock DG, Muntner P. Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) study. Am J Kidney Dis. 2014 May; 63(5):781-8.
78. Calhoun DA, Booth JN, Oparil S, Irvin MR, Shimbo D, Lackland DT, Howard G, Safford MM, Muntner P. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension. 2014 Mar; 63(3):451-8.
79. Santos RC, de Faria AP, Barbaro NR, Modolo R, Ferreira-Melo SE, Matos-Souza JR, Coelho OR, Yugar-Toledo JC, Fontana V, Calhoun D, Moreno H. Tadalafil-induced improvement in left ventricular diastolic function in resistant hypertension. Eur J Clin Pharmacol. 2014 Feb; 70(2):147-54.
80. Kumar N, Calhoun DA, Dudenbostel T. Management of patients with resistant hypertension: current treatment options. Integr Blood Press Control. 2013 Oct 22; 6:139-51.
81. Sim JJ, Bhandari SK, Shi J, Liu IL, Calhoun DA, McGlynn EA, Kalantar-Zadeh K, Jacobsen SJ. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc. 2013 Oct; 88(10):1099-107.
82. Calhoun DA. Apparent and true resistant hypertension: why not the same? J Am Soc Hypertens. 2013 Nov-Dec; 7(6):509-11.
83. Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, Calhoun DA. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension. 2013 Oct; 62(4):691-7.
84. Flores FX, Ojeda FJ, Calhoun DA. Bartter syndrome: presentation in an extremely premature neonate. J Perinatol. 2013 Aug; 33(8):661-2.
85. Pimenta E, Calhoun DA. Response. Chest. 2013 Aug; 144(2):720.
86. Tanner RM, Calhoun DA, Bell EK, Bowling CB, Gutiérrez OM, Irvin MR, Lackland DT, Oparil S, Warnock D, Muntner P. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol. 2013 Sep; 8(9):1583-90.
87. Calhoun DA, Lacourcière Y, Crikelair N, Jia Y, Glazer RD. Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension. Curr Med Res Opin. 2013 Aug; 29(8):901-10.
88. Eirin A, Zhu XY, Woollard JR, Herrmann SM, Gloviczki ML, Saad A, Juncos LA, Calhoun DA, Rule AD, Lerman A, Textor SC, Lerman LO. Increased circulating inflammatory endothelial cells in blacks with essential hypertension. Hypertension. 2013 Sep; 62(3):585-91.
89. Guichard JL, Clark D, Calhoun DA, Ahmed MI. Aldosterone receptor antagonists: current perspectives and therapies. Vasc Health Risk Manag. 2013; 9:321-31.
90. Pimenta E, Stowasser M, Gordon RD, Harding SM, Batlouni M, Zhang B, Oparil S, Calhoun DA. Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism. Chest. 2013 Apr; 143(4):978-983.
91. Shimbo D, Levitan EB, Booth JN, Calhoun DA, Judd SE, Lackland DT, Safford MM, Oparil S, Muntner P. The contributions of unhealthy lifestyle factors to apparent resistant hypertension: findings from the Reasons for Geographic And Racial Differences in Stroke (REGARDS) study. J Hypertens. 2013 Feb; 31(2):370-6.
92. Moreno H, Calhoun DA. True resistant hypertension: definition and prevalence. J Hypertens. 2012 Nov; 30(11):2241-2; author reply 2242-2243.
93. Calhoun DA. Hyperaldosteronism as a common cause of resistant hypertension. Annu Rev Med. 2013; 64:233-47.
94. Ashraf AP, Fisher G, Alvarez J, Dudenbostel T, Calhoun DA, Szalai AJ, Gower BA. Associations of C-Reactive Protein to Indices of Vascular Health and the Influence of Serum 25(OH)D Status in Healthy Adults. J Nutr Metab. 2012; 2012:475975.
95. Gorelick PB, Nyenhuis D. Blood pressure and treatment of persons with hypertension as it relates to cognitive outcomes including executive function. J Am Soc Hypertens. 2012 Sep-Oct; 6(5):309-15.
96. Irvin MR, Shimbo D, Mann DM, Reynolds K, Krousel-Wood M, Limdi NA, Lackland DT, Calhoun DA, Oparil S, Muntner P. Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension. J Clin Hypertens (Greenwich). 2012 Oct; 14(10):694-700.
97. Alessi A, Brandão AA, Coca A, Cordeiro AC, Cordeiro A, Nogueira AR, Diógenes de Magalhães F, Feitosa A, Amodeo C, Saad Rodrigues CI, Rodrigues C, Calhoun DA, Calhoun D, Barbosa Coelho E, Barbosa E, Pimenta E, Muxfeldt E, Consolin-Colombo FM, Consolin-Colombo F, Salles G, Rosito G, Moreno H, Martin JF, Yugar JC, Aparecido Bortolotto L, Bortolotto L, Nazário Scala LC, Scala LC, Gonçalves de Sousa M, Souza Md, Gomes MA, Malachias MB, Gus M, Passarelli O, Jardim PC, Toscano PR, Sánchez RA, Sanchez R, Dischinger Miranda R, Miranda RD, Póvoa R, Barroso WK. First Brazilian position on resistant hypertension. Arq Bras Cardiol. 2012 Jul; 99(1):576-85.
98. Alvarez JA, Gower BA, Calhoun DA, Judd SE, Dong Y, Dudenbostel T, Scholl J, Ashraf AP. Serum 25-hydroxyvitamin D and Ethnic Differences in Arterial Stiffness and Endothelial Function. J Clin Med Res. 2012 Jun; 4(3):197-205.
99. Pimenta E, Calhoun DA. Hypertensive crisis: forget the numbers. J Hypertens. 2012 May; 30(5):882-3.
100. Clark D, Ahmed MI, Calhoun DA. Resistant hypertension and aldosterone: an update. Can J Cardiol. 2012 May; 28(3):318-25.
101. Alderman MH, Piller LB, Ford CE, Probstfield JL, Oparil S, Cushman WC, Einhorn PT, Franklin SS, Papademetriou V, Ong ST, Eckfeldt JH, Furberg CD, Calhoun DA, Davis BR. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2012 May; 59(5):926-33.
102. Ahmed MI, Desai RV, Gaddam KK, Venkatesh BA, Agarwal S, Inusah S, Lloyd SG, Denney TS, Calhoun D, Dell'italia LJ, Gupta H. Relation of torsion and myocardial strains to LV ejection fraction in hypertension. JACC Cardiovasc Imaging. 2012 Mar; 5(3):273-81.
103. Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence, and prognosis. Circulation. 2012 Apr 03; 125(13):1594-6.
104. Clark D, Guichard JL, Calhoun DA, Ahmed MI. Recent advancements in the treatment of resistant hypertension. Postgrad Med. 2012 Jan; 124(1):67-73.
105. Judd E, Calhoun DA. Hypertension and orthostatic hypotension in older patients. J Hypertens. 2012 Jan; 30(1):38-9.
106. Textor SC, Gloviczki ML, Flessner MF, Calhoun DA, Glockner J, Grande JP, McKusick MA, Cha SS, Lerman LO. Association of filtered sodium load with medullary volumes and medullary hypoxia in hypertensive African Americans as compared with whites. Am J Kidney Dis. 2012 Feb; 59(2):229-37.
107. Acelajado MC, Pisoni R, Dudenbostel T, Dell'Italia LJ, Cartmill F, Zhang B, Cofield SS, Oparil S, Calhoun DA. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich). 2012 Jan; 14(1):7-12.
108. Acelajado MC, Pisoni R, Dudenbostel T, Oparil S, Calhoun DA, Glasser SP. Both morning and evening dosing of nebivolol reduces trough mean blood pressure surge in hypertensive patients. J Am Soc Hypertens. 2012 Jan-Feb; 6(1):66-72.
109. Calhoun DA, White WB, Krum H, Guo W, Bermann G, Trapani A, Lefkowitz MP, Ménard J. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation. 2011 Nov 01; 124(18):1945-55.
110. Epstein M, Calhoun DA. Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics. J Clin Hypertens (Greenwich). 2011 Sep; 13(9):644-8.
111. Sim JJ, Yan EH, Liu IL, Rasgon SA, Kalantar-Zadeh K, Calhoun DA, Derose SF. Positive relationship of sleep apnea to hyperaldosteronism in an ethnically diverse population. J Hypertens. 2011 Aug; 29(8):1553-9.
112. Pisoni R, Acelajado MC, Cartmill FR, Dudenbostel T, Dell'Italia LJ, Cofield SS, Oparil S, Calhoun DA. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. J Hum Hypertens. 2012 Aug; 26(8):502-6.
113. Dudenbostel T, Calhoun DA. Resistant hypertension, obstructive sleep apnoea and aldosterone. J Hum Hypertens. 2012 May; 26(5):281-7.
114. Quinaglia T, Martins LC, Figueiredo VN, Santos RC, Yugar-Toledo JC, Martin JF, Demacq C, Pimenta E, Calhoun DA, Moreno H. Non-dipping pattern relates to endothelial dysfunction in patients with uncontrolled resistant hypertension. J Hum Hypertens. 2011 Nov; 25(11):656-64.
115. Ahmed MI, Calhoun DA. Resistant hypertension: bad and getting worse. Hypertension. 2011 Jun; 57(6):1045-6.
116. Yugar-Toledo JC, Martin JF, Krieger JE, Pereira AC, Demacq C, Coelho OR, Pimenta E, Calhoun DA, Júnior HM. Gene variation in resistant hypertension: multilocus analysis of the angiotensin 1-converting enzyme, angiotensinogen, and endothelial nitric oxide synthase genes. DNA Cell Biol. 2011 Aug; 30(8):555-64.
117. Lacourcière Y, Crikelair N, Glazer RD, Yen J, Calhoun DA. 24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. J Hum Hypertens. 2011 Oct; 25(10):615-22.
118. Acelajado MC, Calhoun DA. Aldosteronism and resistant hypertension. Int J Hypertens. 2011 Jan 20; 2011:837817.
119. Levine DA, Calhoun DA, Prineas RJ, Cushman M, Howard VJ, Howard G. Moderate waist circumference and hypertension prevalence: the REGARDS Study. Am J Hypertens. 2011 Apr; 24(4):482-8.
120. Levine DA, Lewis CE, Williams OD, Safford MM, Liu K, Calhoun DA, Kim Y, Jacobs DR, Kiefe CI. Geographic and demographic variability in 20-year hypertension incidence: the CARDIA study. Hypertension. 2011 Jan; 57(1):39-47.
121. Ahmed MI, Calhoun DA. Apparent resistant hypertension and medication adherence. Hypertens Res. 2011 Jan; 34(1):41-2.
122. Acelajado MC, Calhoun DA. Resistant hypertension, secondary hypertension, and hypertensive crises: diagnostic evaluation and treatment. Cardiol Clin. 2010 Nov; 28(4):639-54.
123. Pimenta E, Calhoun DA. Treatment of resistant hypertension. J Hypertens. 2010 Nov; 28(11):2194-5.
124. Martins LC, Figueiredo VN, Quinaglia T, Boer-Martins L, Yugar-Toledo JC, Martin JF, Demacq C, Pimenta E, Calhoun DA, Moreno H. Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness. J Hum Hypertens. 2011 Sep; 25(9):532-8.
125. Acelajado MC, Pimenta E, Calhoun DA. Salt and aldosterone: a concert of bad effects. Hypertension. 2010 Nov; 56(5):804-5.
126. Gonzaga CC, Gaddam KK, Ahmed MI, Pimenta E, Thomas SJ, Harding SM, Oparil S, Cofield SS, Calhoun DA. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med. 2010 Aug 15; 6(4):363-8.
127. Calhoun DA, Sharma K. The role of aldosteronism in causing obesity-related cardiovascular risk. Cardiol Clin. 2010 Aug; 28(3):517-27.
128. Calhoun DA, Harding SM. Sleep and hypertension. Chest. 2010 Aug; 138(2):434-43.
129. Calhoun DA. Obstructive sleep apnea and hypertension. Curr Hypertens Rep. 2010 Jun; 12(3):189-95.
130. Gaddam K, Corros C, Pimenta E, Ahmed M, Denney T, Aban I, Inusah S, Gupta H, Lloyd SG, Oparil S, Husain A, Dell'Italia LJ, Calhoun DA. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension. 2010 May; 55(5):1137-42.
131. Calhoun DA, Crikelair NA, Yen J, Glazer RD. Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety. Adv Ther. 2009 Nov; 26(11):1012-23.
132. Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM, Calhoun DA. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens. 2010 Aug; 24(8):532-7.
133. Zappe DH, Palmer BF, Calhoun DA, Purkayastha D, Samuel R, Jamerson KA. Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in patients with stage-1 or stage-2 hypertension. J Hum Hypertens. 2010 Jul; 24(7):483-91.
134. Acelajado MC, Calhoun DA, Oparil S. Reduction of blood pressure in patients with treatment-resistant hypertension. Expert Opin Pharmacother. 2009 Dec; 10(18):2959-71.
135. Pisoni R, Ahmed MI, Calhoun DA. Characterization and treatment of resistant hypertension. Curr Cardiol Rep. 2009 Nov; 11(6):407-13.
136. Ahmed MI, Pisoni R, Calhoun DA. Current options for the treatment of resistant hypertension. Expert Rev Cardiovasc Ther. 2009 Nov; 7(11):1385-93.
137. Feng W, Nagaraj H, Gupta H, Lloyd SG, Aban I, Perry GJ, Calhoun DA, Dell'Italia LJ, Denney TS. A dual propagation contours technique for semi-automated assessment of systolic and diastolic cardiac function by CMR. J Cardiovasc Magn Reson. 2009 Aug 13; 11:30.
138. Calhoun DA. Use of single-pill combination therapy in the evolving paradigm of hypertension management. Expert Opin Pharmacother. 2009 Aug; 10(12):1869-74.
139. Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ, Calhoun DA. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009 Sep; 54(3):475-81.
140. Acelajado MC, Calhoun DA. Resistant hypertension: who and how to evaluate. Curr Opin Cardiol. 2009 Jul; 24(4):340-4.
141. Calhoun DA, Lacourcière Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension. 2009 Jul; 54(1):32-9.
142. Pimenta E, Calhoun DA, Oparil S. Sleep apnea, aldosterone, and resistant hypertension. Prog Cardiovasc Dis. 2009 Mar-Apr; 51(5):371-80.
143. Pimenta E, Calhoun DA. Aldosterone and metabolic dysfunction: an unresolved issue. Hypertension. 2009 Apr; 53(4):585-6.
144. Gaddam KK, Pimenta E, Husain S, Calhoun DA. Aldosterone and cardiovascular disease. Curr Probl Cardiol. 2009 Feb; 34(2):51-84.
145. Flack JM, Calhoun DA, Satlin L, Barbier M, Hilkert R, Brunel P. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens. 2009 Jul; 23(7):479-89.
146. Gonzaga CC, Calhoun DA. Resistant hypertension and hyperaldosteronism. Curr Hypertens Rep. 2008 Dec; 10(6):496-503.
147. Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens. 2008 Nov-Dec; 2(6):462-8.
148. Biederman RW, Doyle M, Young AA, Devereux RB, Kortright E, Perry G, Bella JN, Oparil S, Calhoun D, Pohost GM, Dell'Italia LJ. Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy. Hypertension. 2008 Aug; 52(2):279-86.
149. Gonzaga CC, Calhoun DA. 2008 American Heart Association Statement on diagnosis, evaluation, and treatment of resistant hypertension: what should we remember in everyday practice? Pol Arch Med Wewn. 2008 Jul-Aug; 118(7-8):396-7.
150. Calhoun DA, Glazer RD, Pettyjohn FS, Coenen PD, Zhao Y, Grosso A. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension. Curr Med Res Opin. 2008 Aug; 24(8):2303-11.
151. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008 Jun 24; 117(25):e510-26.
152. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, Calhoun DA. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008 Jun 09; 168(11):1159-64.
153. White WB, Calhoun DA, Samuel R, Taylor AA, Zappe DH, Purkayastha D. Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? the valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTATE) trial. J Clin Hypertens (Greenwich). 2008 Jun; 10(6):450-8.
154. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008 Jun; 51(6):1403-19.
155. Li S, Chen SC, Shlipak M, Bakris G, McCullough PA, Sowers J, Stevens L, Jurkovitz C, McFarlane S, Norris K, Vassalotti J, Klag MJ, Brown WW, Narva A, Calhoun D, Johnson B, Obialo C, Whaley-Connell A, Becker B, Collins AJ. Low birth weight is associated with chronic kidney disease only in men. Kidney Int. 2008 Mar; 73(5):637-42.
156. Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Aban I, Oparil S, Calhoun DA. Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension. 2008 Feb; 51(2):339-44.
157. Pimenta E, Calhoun DA. Resistant hypertension and aldosteronism. Curr Hypertens Rep. 2007 Nov; 9(5):353-9.
158. Ahmed A, Calhoun D. High blood pressure in older adults: a conversation with Dr David Calhoun. Am J Geriatr Cardiol. 2007 Nov-Dec; 16(6):391-2.
159. Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Cofield SS, Oparil S, Calhoun DA. Aldosterone excess and resistance to 24-h blood pressure control. J Hypertens. 2007 Oct; 25(10):2131-7.
160. Calhoun DA. Is there an unrecognized epidemic of primary aldosteronism? Pro. Hypertension. 2007 Sep; 50(3):447-53; discussion 447-53.
161. Pimenta E, Calhoun DA, Oparil S. Mechanisms and treatment of resistant hypertension. Arq Bras Cardiol. 2007 Jun; 88(6):683-92.
162. Epstein M, Calhoun DA. The role of aldosterone in resistant hypertension: implications for pathogenesis and therapy. Curr Hypertens Rep. 2007 Apr; 9(2):98-105.
163. Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest. 2007 Feb; 131(2):453-9.
164. Calhoun DA. Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. J Clin Hypertens (Greenwich). 2007 Jan; 9(1 Suppl 1):19-24.
165. Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, Zhang J. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007 Jan; 25(1):217-26.
166. Calhoun DA. Aldosterone and cardiovascular disease: smoke and fire. Circulation. 2006 Dec 12; 114(24):2572-4.
167. Pimenta E, Calhoun DA. Primary aldosteronism: diagnosis and treatment. J Clin Hypertens (Greenwich). 2006 Dec; 8(12):887-93.
168. Calhoun DA. Aldosteronism and hypertension. Clin J Am Soc Nephrol. 2006 Sep; 1(5):1039-45.
169. Pimenta E, Calhoun DA. Aldosterone, dietary salt, and renal disease. Hypertension. 2006 Aug; 48(2):209-10.
170. Calhoun DA. Use of aldosterone antagonists in resistant hypertension. Prog Cardiovasc Dis. 2006 May-Jun; 48(6):387-96.
171. Gaddam KK, Pratt-Ubunama MN, Calhoun DA. Aldosterone antagonists: effective add-on therapy for the treatment of resistant hypertension. Expert Rev Cardiovasc Ther. 2006 May; 4(3):353-9.
172. Nishizaka MK, Calhoun DA. Cardiovascular risk of systolic versus diastolic blood pressure in Western and non-Western countries. J Hypertens. 2006 Mar; 24(3):435-6.
173. Calhoun DA. Resistant or difficult-to-treat hypertension. J Clin Hypertens (Greenwich). 2006 Mar; 8(3):181-6.
174. Nishizaka MK, Calhoun DA. Primary aldosteronism: diagnostic and therapeutic considerations. Curr Cardiol Rep. 2005 Nov; 7(6):412-7.
175. Nishizaka MK, Calhoun DA. The role of aldosterone antagonists in the management of resistant hypertension. Curr Hypertens Rep. 2005 Oct; 7(5):343-7.
176. Raitt MH, Connor WE, Morris C, Kron J, Halperin B, Chugh SS, McClelland J, Cook J, MacMurdy K, Swenson R, Connor SL, Gerhard G, Kraemer DF, Oseran D, Marchant C, Calhoun D, Shnider R, McAnulty J. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA. 2005 Jun 15; 293(23):2884-91.
177. Pratt-Ubunama MN, Nishizaka MK, Calhoun DA. Aldosterone antagonism: an emerging strategy for effective blood pressure lowering. Curr Hypertens Rep. 2005 Jun; 7(3):186-92.
178. Berecek KH, Calhoun D. Clinical trials report. Metabolic effects of carvedilol versus metoprolol in patients with type 2 diabetes mellitus and hypertension. Curr Hypertens Rep. 2005 Jun; 7(3):204-5.
179. Nishizaka MK, Pratt-Ubunama M, Zaman MA, Cofield S, Calhoun DA. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens. 2005 Jun; 18(6):805-12.
180. Egan BM, Papademetriou V, Wofford M, Calhoun D, Fernandes J, Riehle JE, Nesbitt S, Michelson E, Julius S. Metabolic syndrome and insulin resistance in the TROPHY sub-study: contrasting views in patients with high-normal blood pressure. Am J Hypertens. 2005 Jan; 18(1):3-12.
181. Calhoun DA, Grassi G. Weight gain and hypertension: the chicken-egg question revisited. J Hypertens. 2004 Oct; 22(10):1869-71.
182. Nishizaka MK, Calhoun DA. Use of aldosterone antagonists in resistant hypertension. J Clin Hypertens (Greenwich). 2004 Aug; 6(8):458-60.
183. Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Calhoun DA. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation. 2004 Jun 15; 109(23):2857-61.
184. Jin M, Rosario W, Watler E, Calhoun DH. Development of a large-scale HPLC-based purification for the urease from Staphylococcus leei and determination of subunit structure. Protein Expr Purif. 2004 Mar; 34(1):111-7.
185. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension. 2004 Mar; 43(3):518-24.
186. Calhoun DA, Nishizaka MK, Zaman MA, Harding SM. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest. 2004 Jan; 125(1):112-7.
187. Hicken BL, Calhoun DA, Barton JC, Tucker DC. Attitudes about and psychosocial outcomes of HFE genotyping for hemochromatosis. Genet Test. 2004; 8(2):90-7.
188. Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med. 2003 Nov 04; 139(9):761-76.
189. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003 Nov; 16(11 Pt 1):925-30.
190. Aqel RA, Zoghbi GJ, Baldwin SA, Auda WS, Calhoun DA, Coffey CS, Perry GJ, Iskandrian AE. Prevalence of renal artery stenosis in high-risk veterans referred to cardiac catheterization. J Hypertens. 2003 Jun; 21(6):1157-62.
191. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002 Dec; 40(6):892-6.
192. Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens. 2002 Nov; 20(11):2257-67.
193. White WB, Sica DA, Calhoun D, Mansoor GA, Anders RJ. Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising. Am Heart J. 2002 Oct; 144(4):657-65.
194. Zaman MA, Oparil S, Calhoun DA. Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discov. 2002 Aug; 1(8):621-36.
195. Calhoun DA, Zaman MA, Nishizaka MK. Resistant hypertension. Curr Hypertens Rep. 2002 Jun; 4(3):221-8.
196. DeJesus V, Rios I, Davis C, Chen Y, Calhoun D, Zakeri Z, Hubbard K. Induction of apoptosis in human replicative senescent fibroblasts. Exp Cell Res. 2002 Mar 10; 274(1):92-9.
197. Grassi G, Calhoun DA. Sympathetic-vascular interactions: further evidence in kidney transplantation. J Hypertens. 2002 Mar; 20(3):379-81.
198. Maheshwari A, Christensen RD, Calhoun DA. Immune-mediated neutropenia in the neonate. Acta Paediatr Suppl. 2002; 91(438):98-103.
199. Carter AR, Zhou ZH, Calhoun DA, Bubien JK. Hyperactive ENaC identifies hypertensive individuals amenable to amiloride therapy. Am J Physiol Cell Physiol. 2001 Nov; 281(5):C1413-21.
200. Calhoun DA, Wei CC, Zhu S, Bradley WE, Dell'Italia LJ. Enalaprilat blunts reflexive increases in cardiac interstitial norepinephrine in conscious rats. J Hypertens. 2001 Nov; 19(11):2025-9.
201. Elliott WJ, Calhoun DA, DeLucca PT, Gazdick LP, Kerns DE, Zeldin RK. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. Clin Ther. 2001 Aug; 23(8):1166-79.
202. Payami H, Lee N, Zareparsi S, Gonzales McNeal M, Camicioli R, Bird TD, Sexton G, Gancher S, Kaye J, Calhoun D, Swanson PD, Nutt J. Parkinson's disease, CYP2D6 polymorphism, and age. Neurology. 2001 May 22; 56(10):1363-70.
203. Sakawi Y, Tarpey M, Chen YF, Calhoun DA, Connor MG, Chestnut DH, Parks DA. Evaluation of low-dose endotoxin administration during pregnancy as a model of preeclampsia. Anesthesiology. 2000 Dec; 93(6):1446-55.
204. Calhoun DA, Lunøe M, Du Y, Hutson AD, Veerman M, Christensen RD. Granulocyte colony-stimulating factor serum and urine concentrations in neutropenic neonates before and after intravenous administration of recombinant granulocyte colony-stimulating factor. Pediatrics. 2000 Feb; 105(2):392-7.
205. Alper AB, Calhoun DA. Contemporary management of refractory hypertension. Curr Hypertens Rep. 1999 Oct; 1(5):402-7.
206. Fang Z, Sripairojthikoon W, Calhoun DA, Zhu S, Berecek KH, Wyss JM. Interaction between lifetime captopril treatment and NaCI-sensitive hypertension in spontaneously hypertensive rats and Wistar-Kyoto rats. J Hypertens. 1999 Jul; 17(7):983-91.
207. Calhoun DA, Zhu S. Pretreatment with enalaprilat blunts nicardipine-induced sympathetic activation in spontaneously hypertensive and Wistar-Kyoto rats. J Hypertens. 1999 Apr; 17(4):507-12.
208. Oparil S, Calhoun DA. Managing the patient with hard-to-control hypertension. Am Fam Physician. 1998 Mar 01; 57(5):1007-14, 1019-20.
209. Calhoun DA, Mutinga ML. Race, family history of hypertension, and sympathetic response to cold pressor testing. Blood Press. 1997 Jul; 6(4):209-13.
210. Calhoun DA, Oparil S. High blood pressure in women. Int J Fertil Womens Med. 1997 May-Jun; 42(3):198-205.
211. Zhu ST, Chen YF, Wyss JM, Nakao K, Imura H, Oparil S, Calhoun DA. Atrial natriuretic peptide blunts arterial baroreflex in spontaneously hypertensive rats. Hypertension. 1996 Feb; 27(2):297-302.
212. Calhoun DA, Oparil S. Racial differences in the pathogenesis of hypertension. Am J Med Sci. 1995 Dec; 310 Suppl 1:S86-90.
213. Calhoun DA, Zhu ST, Chen YF, Oparil S. Gender and dietary NaCl in spontaneously hypertensive and Wistar-Kyoto rats. Hypertension. 1995 Aug; 26(2):285-9.
214. Calhoun DA, Oparil S. Hypertensive crisis since FDR--a partial victory. N Engl J Med. 1995 Apr 13; 332(15):1029-30.
215. Calhoun DA, Mutinga ML, Wyss JM, Oparil S. Muscle sympathetic nervous system activity in black and Caucasian hypertensive subjects. J Hypertens. 1994 Nov; 12(11):1291-6.
216. Calhoun DA, Zhu S, Wyss JM, Oparil S. Diurnal blood pressure variation and dietary salt in spontaneously hypertensive rats. Hypertension. 1994 Jul; 24(1):1-7.
217. Grassi G, Seravalle G, Calhoun DA, Bolla GB, Giannattasio C, Marabini M, Del Bo A, Mancia G. Mechanisms responsible for sympathetic activation by cigarette smoking in humans. Circulation. 1994 Jul; 90(1):248-53.
218. Grassi G, Seravalle G, Calhoun DA, Mancia G. Physical training and baroreceptor control of sympathetic nerve activity in humans. Hypertension. 1994 Mar; 23(3):294-301.
219. Calhoun DA, Mutinga ML, Collins AS, Wyss JM, Oparil S. Normotensive blacks have heightened sympathetic response to cold pressor test. Hypertension. 1993 Dec; 22(6):801-5.
220. Nakamura Y, Calhoun DA, Chen YF, Wyss JM, Oparil S. Excitatory sympathetic reflex in NaCl-sensitive spontaneously hypertensive rats. Hypertension. 1993 Sep; 22(3):285-91.
221. Calhoun DA. Hypertension in blacks: socioeconomic stress and sympathetic nervous system activity. Am J Med Sci. 1992 Nov; 304(5):306-11.
222. Jin H, Yang RH, Calhoun DA, Wyss JM, Oparil S. Atrial natriuretic peptide modulates baroreceptor reflex in spontaneously hypertensive rat. Hypertension. 1992 Sep; 20(3):374-9.
223. Grassi G, Seravalle G, Calhoun DA, Matturri M, Mancia G, Zanchetti A. Monitoring of sympathetic activity in man: physiology and pharmacology. Eur Heart J. 1992 Jun; 13 Suppl A:22-5.
224. Grassi G, Seravalle G, Calhoun D, Bolla GB, Mancia G. Physical exercise in essential hypertension. Chest. 1992 May; 101(5 Suppl):312S-314S.
225. Grassi G, Seravalle G, Calhoun DA, Bolla GB, Zanchetti A, Mancia G. Alterations in sympathetic nerve traffic during cigarette-smoking in man: a preliminary report. J Hypertens Suppl. 1991 Dec; 9(6):S52-3.